GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, New Frontiers Science Park, Harlow, UK.
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7341-4. doi: 10.1016/j.bmcl.2010.10.065. Epub 2010 Nov 10.
The identification and subsequent optimisation of a selective non-peptidic NPY Y2 antagonist series is described. This led to the development of amine 2, a selective, soluble NPY Y2 receptor antagonist with enhanced CNS exposure.
描述了一种选择性非肽类 NPY Y2 拮抗剂系列的鉴定和随后的优化。这导致了胺 2 的开发,一种选择性的、可溶性的 NPY Y2 受体拮抗剂,具有增强的中枢神经系统暴露。